Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts' 2016 Formulary Continues Exclusion Of Gilead’s Harvoni

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharmacy benefit manager released its national preferred formulary for 2016. AbbVie’s Viekira Pak remains the preferred alternative for hepatitis C, while Harvoni remains blocked from coverage.

You may also be interested in...



Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs

Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.

Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs

Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.

Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum

Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel